vs

Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $43.5M, roughly 1.9× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs 20.2%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 24.8%).

Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

DX vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.9× larger
PRCT
$83.1M
$43.5M
DX
Growing faster (revenue YoY)
DX
DX
+511.1% gap
DX
531.3%
20.2%
PRCT
Faster 2-yr revenue CAGR
DX
DX
Annualised
DX
75.8%
24.8%
PRCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
DX
DX
PRCT
PRCT
Revenue
$43.5M
$83.1M
Net Profit
$-31.6M
Gross Margin
64.9%
Operating Margin
-4.1%
Net Margin
-38.1%
Revenue YoY
531.3%
20.2%
Net Profit YoY
-27.9%
EPS (diluted)
$1.59
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DX
DX
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$43.5M
$76.4M
Q3 25
$30.6M
$83.3M
Q2 25
$23.1M
$79.2M
Q1 25
$17.1M
$69.2M
Q4 24
$68.2M
Q3 24
$58.4M
Q2 24
$53.4M
Net Profit
DX
DX
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$-29.8M
Q3 25
$150.4M
$-21.4M
Q2 25
$-13.6M
$-19.6M
Q1 25
$-3.1M
$-24.7M
Q4 24
$-18.9M
Q3 24
$-21.0M
Q2 24
$-25.6M
Gross Margin
DX
DX
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
DX
DX
PRCT
PRCT
Q1 26
-4.1%
Q4 25
-40.6%
Q3 25
-27.8%
Q2 25
-28.0%
Q1 25
-39.7%
Q4 24
-28.9%
Q3 24
-38.4%
Q2 24
-50.3%
Net Margin
DX
DX
PRCT
PRCT
Q1 26
-38.1%
Q4 25
-39.1%
Q3 25
491.3%
-25.7%
Q2 25
-58.8%
-24.7%
Q1 25
-18.0%
-35.8%
Q4 24
-27.6%
Q3 24
-35.9%
Q2 24
-48.0%
EPS (diluted)
DX
DX
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$1.59
$-0.54
Q3 25
$1.08
$-0.38
Q2 25
$-0.14
$-0.35
Q1 25
$-0.06
$-0.45
Q4 24
$-0.34
Q3 24
$-0.40
Q2 24
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DX
DX
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$531.0M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$2.5B
$347.7M
Total Assets
$17.3B
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DX
DX
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$531.0M
$286.5M
Q3 25
$491.0M
$294.3M
Q2 25
$387.5M
$302.7M
Q1 25
$327.4M
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
DX
DX
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
DX
DX
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$2.5B
$365.9M
Q3 25
$2.0B
$380.3M
Q2 25
$1.6B
$385.8M
Q1 25
$1.4B
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
DX
DX
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$17.3B
$508.1M
Q3 25
$14.2B
$511.5M
Q2 25
$11.3B
$513.1M
Q1 25
$9.0B
$519.4M
Q4 24
$534.0M
Q3 24
$374.1M
Q2 24
$374.4M
Debt / Equity
DX
DX
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DX
DX
PRCT
PRCT
Operating Cash FlowLast quarter
$120.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DX
DX
PRCT
PRCT
Q1 26
Q4 25
$120.8M
$-10.3M
Q3 25
$68.3M
$-6.6M
Q2 25
$31.9M
$-15.0M
Q1 25
$6.4M
$-17.0M
Q4 24
$-32.4M
Q3 24
$-18.8M
Q2 24
$-15.7M
Free Cash Flow
DX
DX
PRCT
PRCT
Q1 26
Q4 25
$-12.2M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
DX
DX
PRCT
PRCT
Q1 26
Q4 25
-15.9%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
DX
DX
PRCT
PRCT
Q1 26
Q4 25
2.4%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%
Cash Conversion
DX
DX
PRCT
PRCT
Q1 26
Q4 25
Q3 25
0.45×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DX
DX

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons